Form 4: Regulus Therapeutics Director Collier Granted Stock Options

Director Kathryn J. Collier of Regulus Therapeutics Inc. was granted stock options for 60,000 shares on May 20, 2024.

Summary

• Kathryn J. Collier, a director at Regulus Therapeutics Inc., was granted stock options to purchase 60,000 shares of common stock on May 20, 2024.
• The exercise price of these options is $2.01 per share.
• The options vest ratably over twelve months, becoming fully vested one year after the grant date or at the company's next annual shareholder meeting, whichever comes first, contingent upon continuous service.
• The options expire on May 19, 2034.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants, which is generally neutral. It indicates confidence in the company's future, but doesn't provide specific financial details.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Future Outlook

The options will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual shareholder meeting, whichever occurs first, subject to the Reporting Person's continuous service.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded biotechnology companies.
• The size of the grant (60,000 shares) would need to be compared to grants made to directors at comparable companies like Ionis Pharmaceuticals or Alnylam Pharmaceuticals to assess its relative value.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the director's performance leads to company growth.
• The grant incentivizes the director to act in the best interests of the company and its shareholders.

Key Dates